(S)-(-)-2,2'-bis(di-o-tolylphosphino)-1,1'-binaphthyl

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-(-)-2,2'-bis(di-o-tolylphosphino)-1,1'-binaphthyl
• 英文别名: (S)-TolBINAP；Tol-BINAP；(S)-2,2'-bis[bis(2-methylphenyl)phosphino]-1,1'-binaphthyl；2,2'-Bis[di(o-tolyl)phosphino]-1,1'-binaphthyl；[1-[2-bis(2-methylphenyl)phosphanylnaphthalen-1-yl]naphthalen-2-yl]-bis(2-methylphenyl)phosphane
• 化学式: C₄₈H₄₀P₂
• 分子量: 678.793
• InChiKey: YQQDSYDGVSTZQF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  12.9
• 重原子数：
  50
• 可旋转键数：
  7
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  (S)-(-)-2,2'-bis(di-o-tolylphosphino)-1,1'-binaphthyl 在 双氧水 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 以98%的产率得到(S)-2,2'-bis(di-o-tolylphosphinyl)-1,1'-binaphthyl
  参考文献：
  名称：

  双功能手性氧化膦催化剂对酮亚胺的不对称氢化硅烷化的评价

  摘要：

  已经制备了一系列双官能氧化膦，并评价了其为三氯硅烷介导的酮亚胺的不对称氢化硅烷化的催化剂。双膦氧化物，羟基膦氧化物和联芳基膦氧化物都表现出良好的催化活性，但是对映选择性差至中等。甲双- P -手性膦氧化物显示的60％的最高的对映选择性。

  DOI：

  10.1016/j.tet.2019.130733
• 作为产物：
  描述：

  di(o-tolyl)phosphine borane 、 (S)-(+)-1,1'-联-2-萘酚二(三氟甲磺酸酯) 在 1,2-双(二苯基膦)乙烷氯化镍 三乙烯二胺 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 96.5h， 以55.5%的产率得到(S)-(-)-2,2'-bis(di-o-tolylphosphino)-1,1'-binaphthyl
  参考文献：
  名称：

  PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS

  摘要：

  公开号：

  EP1452537B1
• 作为试剂：
  描述：

  cyclopent-4-ene-1,3-diyl diethyl dicarbonate 、 苯硼酸 在 [Rh(OH)(cod)]2 、 (S)-(-)-2,2'-bis(di-o-tolylphosphino)-1,1'-binaphthyl 、 caesium carbonate 作用下， 以 四氢呋喃 为溶剂， 生成 trans-4-phenylcyclopent-2-enyl ethyl carbonate 、 trans-4-phenylcyclopent-2-enyl ethyl carbonate 、 trans-2-phenylcyclopent-3-enyl ethyl carbonate
  参考文献：
  名称：

  铑（I）催化芳基硼酸加成对内消旋环戊烯-1,4-二醇的不对称作用的配体控制选择性

  摘要：

  的对映体选择性高desymmetrization内消旋环戊-2-烯-1,4-二乙基二碳酸酯已使用铑催化的不对称烯丙位取代显影。根据所用配体的类型，可以以良好的产率和优异的对映选择性获得两种区域异构产物中的每一种。在铑（I）催化下，双膦P-Phos配体形成反式-1,2-芳基环戊烯醇作为主要产物，而Segphos配体主要导致反式-1,4-芳基环戊烯醇。

  DOI：

  10.1021/jo100391e

文献信息

• [EN] NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS<br/>[FR] NOUVELLES AMIDINES DE THIOPHENE, COMPOSITIONS DE CES AMIDINES ET PROCEDE POUR TRAITER DES MALADIES ET DES ETATS MEDIES PAR LE COMPLEMENT
  申请人：DIMENSIONAL PHARM INC

  公开号：WO2003099805A1

  公开（公告）日：2003-12-04

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.

  揭示了一种治疗急性或慢性疾病症状的方法，该方法通过补体级联的经典途径介导，包括向需要此类治疗的哺乳动物施用化合物I的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中规范中定义了R1、R2、R3、R4和R7，Z为SO或SO2，Ar为本规范中定义的芳香族或杂环芳基。
• Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20040009995A1

  公开（公告）日：2004-01-15

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R 1 , R 2 , R 3 , R 4 and R 7 are defined in the specification, Z is SO or SO 2 , and Ar is an aromatic or heteroaromatic group as defined herein.

  揭示了一种治疗急性或慢性疾病症状的方法，该方法通过补体级联的经典途径介导，包括向需要此类治疗的哺乳动物施用公式I的化合物的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中在规范中定义了R1、R2、R3、R4和R7，Z为SO或SO2，Ar为本文中定义的芳香族或杂环芳基。
• METHOD FOR PRODUCING 3-METHYL-CYCLOPENTADECENONES, METHOD FOR PRODUCING (R)- AND (S)- MUSCONE, AND METHOD FOR PRODUCING OPTICALLY ACTIVE MUSCONE
  申请人：Doya Masaharu

  公开号：US20110172465A1

  公开（公告）日：2011-07-14

  By intramolecular condensation reaction of 2,15-hexadecanedione in a gaseous phase with a compound of a Group II element of the Periodic Table as a catalyst, 3-methyl-cyclopentadecenones is generated. Magnesium oxide, calcium oxide, or zinc oxide is desirable as the catalyst for the intramolecular condensation reaction. (R)- and (S)-muscone is generated by subjecting 3-methyl-cyclopentadecenones obtained as above to hydrogenation by using a catalyst. Palladium catalyst is desirable as the hydrogenation catalyst. Optically active muscone is generated by separating 3-methyl-cyclopentadecenones into respective components thereof by means of precision distillation and subsequently subjecting the separated 3-methyl-cyclopentadecenones to asymmetric hydrogenation by using an optically active ruthenium complex catalyst. The production methods described above enable easy and economical production of 3-methyl-cyclopentadecenones, (R)- and (S)-muscone, and optically active muscone.

  通过在气相中使用周期表第二元素化合物作为催化剂，对2,15-己十二酮进行分子内缩合反应，生成3-甲基环戊十五烯酮。镁氧化物、钙氧化物或氧化锌是分子内缩合反应的理想催化剂。通过使用催化剂对上述获得的3-甲基环戊十五烯酮进行加氢反应，生成(R)-和(S)-麝香酮。钯催化剂是加氢反应的理想催化剂。通过精密蒸馏将3-甲基环戊十五烯酮分离成各自的组分，然后使用光学活性钌配合物催化剂对分离的3-甲基环戊十五烯酮进行不对称加氢反应，可以生成光学活性麝香酮。上述生产方法可实现3-甲基环戊十五烯酮、(R)-和(S)-麝香酮以及光学活性麝香酮的易于和经济的生产。
• Process for preparation of diphosphine compounds and intermediates for the process
  申请人：Goto Mitsutaka

  公开号：US20050027124A1

  公开（公告）日：2005-02-03

  A production method of a compound represented by the formula wherein R 1a , R 1b , R 1c , R 1d , R 1e , R 1f , R 2a , R 2b , R 2c , R 2d , R 2e an R 2f are the same or different and each is a hydrogen atom and the like, and R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are the same or different and each is a hydrogen atom and the like, or a salt thereof, which comprises reacting a compound represented by the formula wherein X is a leaving group and other symbols are as defined above, or a salt thereof, with a phosphine-borane complex represented by the formula wherein the symbols are as defined above, or a salt thereof, in a solvent in the presence of an amine and a nickel catalyst, is provided.

  提供一种化合物的生产方法，该化合物的化学式为其中R1a，R1b，R1c，R1d，R1e，R1f，R2a，R2b，R2c，R2d，R2e和R2f相同或不同，每个都是氢原子等，R3，R4，R5，R6，R7，R8，R9和R10相同或不同，每个都是氢原子等，或其盐，包括在存在胺和镍催化剂的溶剂中，将化学式为其中X是离去基团，其他符号如上所定义的化合物或其盐与化学式为其中符号如上所定义的膦硼烷复合物或其盐反应。
• Amino-heterocycles as vr-1 antagonists for treating pain
  申请人：Blurton Peter

  公开号：US20060040947A1

  公开（公告）日：2006-02-23

  the present invention provides a compound of formula (I): wherein V represents NR 5 , O, S, SO or S(O) 2 ; W and X each independently represent CH or N; Y represents N, CH or C—Ar 2 , with the proviso that at least one, but no more than two, of W, X and Y are N; Z represents CH or C—Ar 2 , with the proviso that when Y is N or CH then Z is C—Ar 2 , and with the further proviso that when Y is C—Ar 2 then Z is CH; Ar 1 represents a fused 9 or 10 membered heterobicyclic ring system containing one, two, three or four heteroatoms selected from nitrogen, oxygen and sulfur, wherein at least one of the rings in said ring system is aromatic; Ar 2 represents an aromatic ring selected from phenyl, pyridyl, pyrimidinyl and pyridazinyl which is optionally fused and substituted; R 1 represents halogen, hydroxy, oxo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, haloC 1-6 alkyl, hydroxyC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, hydroxyC 1-6 alkoxy, C 3-7 cycloalkyl, C 3-7 cycloalkoxy, C 3-5 cycloalkylC 1-4 alkyl, cyano, nitro, SR 6 , SOR 6 , SO 2 R 6 , COR 6 , NR 3 COR 6 , CONR 3 R 4 , NR 3 SO 2 R 6 , SO 2 NR 3 R 4 , —(CH 2 ) m carboxy, esterified —(CH 2 ) m carboxy or —(CH 2 ) m NR 3 R 4 ; R 2 represents hydrogen, halogen, hydroxy, C 1-6 alkyl, haloC 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, unsubstituted phenyl or phenyl substituted with one or two groups selected from halogen, C 1-6 alkyl, haloC 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkoxy or haloC 1-6 alkoxy; R 3 and R 4 are each independently hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl or fluoroC 1-6 alkyl; or R 3 and R 4 and the nitrogen atom to which they are attached together form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or C 1-4 alkoxy, which ring may optionally contain as one of the said ring atoms an oxygen or a sulfur atom, S(O), S(O) 2 , or NR 5 ; R 5 represents hydrogen, C 1-4 alkyl, hydroxyC 1-4 alkyl or C 1-4 alkoxyC 1-4 alkyl; R 6 represents hydrogen, C 1-6 alkyl, fluoroC 1-6 alkyl, C 3-7 cycloalkyl, unsubstituted phenyl, or phenyl substituted with one or two groups selected from halogen, C 1-6 alkyl, haloC 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkoxy or haloC 1-6 alkoxy; m is either zero or an integer from 1 to 4; n is either zero or an integer from 1 to 3; or a pharmaceutically acceptable salt, N-oxide or a prodrug thereof; a pharmaceutical composition comprising it; its use in methods of treatment; use of it for the manufacture of a medicament for treating VR-1 related conditions such as those in which pain and/or inflammation predominate; and methods of treatment using it.

  本发明提供了一种化合物，其化学式为（I）：其中V代表NR5、O、S、SO或S（O）2；W和X各自独立地代表CH或N；Y代表N、CH或C-Ar2，但至少有一个，但不超过两个，W、X和Y是N；Z代表CH或C-Ar2，但当Y为N或CH时，Z为C-Ar2，且进一步规定当Y为C-Ar2时，Z为CH；Ar1代表一个融合的9或10个成员的杂双环环系统，其中包含从氮、氧和硫中选择的一个、两个、三个或四个杂原子，其中至少一个环为芳香环；Ar2代表一种芳香环，选择自苯基、吡啶基、嘧啶基和吡啶嗪基，可选地融合和取代；R1代表卤素、羟基、氧代、C1-6烷基、C2-6烯基、C2-6炔基、卤代C1-6烷基、羟基C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基、羟基C1-6烷氧基、C3-7环烷基、C3-7环烷氧基、C3-5环烷基C1-4烷基、氰基、硝基、SR6、SOR6、SO2R6、COR6、NR3COR6、CONR3R4、NR3SO2R6、SO2NR3R4、-(CH2)m羧基、酯化的-(CH2)m羧基或-(CH2)mNR3R4；R2代表氢、卤素、羟基、C1-6烷基、卤代C1-6烷基、C3-7环烷基、C1-6烷氧基、卤代C1-6烷氧基、未取代苯基或取代一个或两个群的苯基，所述群从卤素、C1-6烷基、卤代C1-6烷基、C3-7环烷基、C1-6烷氧基或卤代C1-6烷氧基中选择；R3和R4各自独立地代表氢、C1-6烷基、C2-6烯基、C2-6炔基、C3-7环烷基或氟代C1-6烷基；或R3和R4及它们所连接的氮原子一起形成4至7个环原子的杂脂环，可选地取代一个或两个群，所述群从羟基或C1-4烷氧基中选择，该环可以选择地包含一个氧原子或硫原子、S（O）、S（O）2或NR5作为其中一个所述环原子；R5代表氢、C1-4烷基、羟基C1-4烷基或C1-4烷氧基C1-4烷基；R6代表氢、C1-6烷基、氟代C1-6烷基、C3-7环烷基、未取代苯基或取代一个或两个群的苯基，所述群从卤素、C1-6烷基、卤代C1-6烷基、C3-7环烷基、C1-6烷氧基或卤代C1-6烷氧基中选择；m为零或1至4的整数；n为零或1至3的整数；或其药学上可接受的盐、N-氧化物或前药；包含它的制药组合物；它在治疗方法中的用途；用于制造治疗VR-1相关疾病的药物，例如疼痛和/或炎症占主导地位的疾病；以及使用它的治疗方法。